Changes in bone mineral density and serum calcium levels after romosozumab treatmet in postmenopausal osteoporosis patients:About short-term results at 6 months

JRCT ID: jRCT1040190111

Registered date:31/01/2020

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: primary osteoprosis
• Date of first enrollment: 31/01/2020
• Target sample size: 60
• Study type: Observational
• Intervention(s): None

Outcome(s)

• Primary Outcome: Bone denisity change

Secondary Outcome

1.Bone turneover makers at 6 months
2.Adverse events at 6 months
3.New fracture at 6 months

Key inclusion & exclusion criteria

• Age minimum: >= 50age old
• Age maximum: < 100age old
• Gender: Female

Include criteria

1.postmenopausal women with osteoporosis
2.patients who used romosozumab for 6 months

Exclude criteria

1.patients who are allergic to romosozumab
2.hypocacemia

Related Information

• Primary Sponsor: Kobayakawa Tomonori